Mark Brantly is Emeritus Professor of Medicine at University of Florida. OpenAlex indexes 288 publications with 13,211 citations (h-index 64); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Mark Brantly, MD, is Emeritus Professor of Medicine at University of Florida. The public record shows 288 publications with 13,211 citations (h-index 64), centered on Chronic Obstructive Pulmonary Disease (COPD) Research, Protease and Inhibitor Mechanisms, Cystic Fibrosis Research Advances. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 4 companies, 2 NIH-funded awards (2002–2009).
- Most recent indexed publication: 2025 · American journal of physiology. Gastrointestinal and liver physiology
- Top research focus: Chronic Obstructive Pulmonary Disease (COPD) Research
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 151.
Clinical & industry
trials, payments and federal fundingContact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Long-Term Follow-up Study of ADVM-043
Sponsor: Adverum Biotechnologies, Inc.
- Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage
Sponsor: University of Florida
- Environment Effect on Six-Minute Walk Test Performance
Sponsor: University of Florida
Industry payments
Updated 24 Oct 2026
4 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20242 payments$18,366openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20241 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20238 payments
NIH funding
Updated 24 Oct 2026
2 NIH research awards on record, funded 2002–2009 per NIH RePORTER. The latest:
- CLINICAL TRIAL: PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF RAAV1-CB-HAAT
University of Florida
FY2009$11,930M01RR000082 - CLINICAL TRIAL: PHASE 3 STUDY OF SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS
University of Florida
FY2009$6,268M01RR000082
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice.
American journal of physiology. Gastrointestinal and liver physiology
Article2025 - Treatment for Alpha-1 Antitrypsin Deficiency: Does Augmentation Therapy Work?
American journal of respiratory and critical care medicine
Comment2023
Most-cited works
by citation count (OpenAlex)- 01Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisArticle1,106 citations2011
- 02
- 03Molecular basis of alpha-1-antitrypsin deficiencyArticle521 citations1988
- 04
- 05
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mark-brantly-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →member.thoracic.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Dekosky, MD
University of Florida
Joe Garcia, MD
University of Florida
Desmond Schatz, MD
University of Florida
Michael Haller, MD
University of Florida
Paul Ridker, MD
Brigham and Women's Hospital
Edward Giovannucci, MD, ScD, MPH
Harvard T.H. Chan School of Public Health
Stephen Chanock, MD
National Cancer Institute (NCI)
Richard Mayeux, MD
Columbia University College of Physicians and Surgeons